Usher Syndrome Market Report 2026

Usher Syndrome Market Overview

• Usher Syndrome market size has reached to $2.24 billion in 2025 • Expected to grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Rising Prevalence Of Inherited Disorders Fueling The Growth Of The Market Due To Increasing Demand For Genetic Testing And Innovative Treatments • Market Trend: Advancing Gene Therapy Clinical Studies For Innovative Treatment Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Usher Syndrome Market?

Usher syndrome is a genetic disorder that affects both hearing and vision, often leading to deafness or hearing loss and a progressive eye condition called retinitis pigmentosa (RP). It is the most common cause of combined deaf-blindness and is inherited in an autosomal recessive pattern. The main types in the usher syndrome market are type 1, type 2, type 3, and other types. Type 1 Usher syndrome is the most severe form of the disorder, characterized by profound deafness from birth, severe balance issues, and early-onset vision loss due to retinitis pigmentosa (RP). The various treatments include devices, drugs, therapy, and others, and diagnosis including electroretinogram, optical coherence tomography, video hysterography, audiology, genetic testing, and other diagnoses. The different distribution channels include hospital pharmacy, retail pharmacy, and others. The different end-users encompass hospitals, specialty clinics, and others.

What Is The Usher Syndrome Market Growth Forecast?

The usher syndrome market size is expected to see strong growth in the next few years. It will grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing research into gene therapy solutions, rising investments in rare disease drug development, growing adoption of personalized medicine approaches, expansion of early intervention programs, increasing collaboration between research institutions and healthcare providers. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, growing focus on gene-based therapeutic approaches, rising use of advanced diagnostic imaging tools, expansion of multidisciplinary treatment pathways, enhanced patient monitoring and disease management models.

What Is The Driver Of The Usher Syndrome Market?

The rising prevalence of inherited disorders is expected to propel the growth of the usher syndrome market going forward. Inherited disorders are genetic conditions passed from parents to offspring through their DNA, often due to mutations in one or more genes. Inherited disorders are on the rise due to increasing parental age, leading to a higher incidence of genetic conditions in newborns. Usher syndrome is a genetic condition that requires early diagnosis, specialized care, and targeted treatments. The increasing awareness and screening for genetic disorders result in more cases of Usher syndrome being identified, leading to higher demand for diagnostic tests, genetic counseling, and therapeutic interventions. For instance, in February 2023, according to the World Health Organization, a Switzerland based international public health agency of the United Nations, congenital disorders were estimated to cause about 240,000 newborn deaths worldwide within the first 28 days of life each year, along with an additional 170,000 deaths among children aged 1 month to 5 years. Therefore, the rising prevalence of inherited disorders will drive the usher syndrome industry.

Key Players In The Global Usher Syndrome Market

Major companies operating in the usher syndrome market are Cochlear Ltd, Advanced Bionics AG, Spark Therapeutics, Editas Medicine Inc, ProQR Therapeutics NV, Odylia Therapeutics, ReNeuron Group plc, Sensorion SAS, Gensight Biologics, AAVantgarde Bio, Laboratoires Théa, Atsena Therapeutics, Nanoscope Therapeutics, Nacuity Pharmaceuticals, Janus Biotechnology, Eiger BioPharmaceuticals, Audentes Therapeutics, Sarepta Therapeutics, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals, UniQure

Global Usher Syndrome Market Trends and Insights

Major companies operating in the usher syndrome market are focusing on clinical studies to develop gene therapies and innovative treatments that can slow or reverse vision and hearing loss. Clinical studies aim to improve early diagnosis, enhance assistive technologies, and explore potential drug-based interventions for better disease management. For example, in October 2024, AAVantgarde Bio, an Italy-based biotechnology company, launched the LUCE-1 trial, a Phase I/II clinical study aimed at evaluating the safety and efficacy of its gene therapy, AAVB-081, for treating retinitis pigmentosa associated with Usher Syndrome type 1B (USH1B). The LUCE-1 trial aims to assess the safety and tolerability of AAVB-081, which delivers a functional copy of the MYO7A gene crucial for retinal health.

What Are Latest Mergers And Acquisitions In The Usher Syndrome Market?

In December 2023, Laboratoires Théa, a France-based pharma company, acquired sepofarsen and ultevursen from ProQR Therapeutics for an undisclosed amount. The acquisition aims to enable Laboratoires Théa to advance the clinical development of sepofarsen and ultevursen for treating inherited retinal diseases such as LCA10 and Usher syndrome 2A. ProQR Therapeutics NV is a Netherlands-based biotechnology company focusing on usher syndrome type 2 treatment.

What Defines the Usher Syndrome Market?

The usher syndrome market consists of revenues earned by entities by providing services such as audiology services, vision rehabilitation, genetic counseling, and mobility training. The market value includes the value of related goods sold by the service provider or included within the service offering. The usher syndrome market also includes sales of hearing aids, cochlear implants, assistive listening devices, and low-vision aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Usher Syndrome Market Report 2026?

The usher syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the usher syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.